ArticleJournal of general internal medicine2026
One Pill to Rule Them All: The Role of Single-Pill Combinations in Optimizing Blood Pressure Control.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension control in the United States (U.S.) remains suboptimal, perpetuating preventable risk for primary and secondary cardiovascular events. Single-pill combinations (SPCs) that contain two or more agents have improved adherence and outcomes in conditions such as human immunodeficiency virus (HIV) and heart failure, yet remain underused in hypertension care. Based on evidence of improved adherence and reductions in cardiovascular events and all-cause mortality, the recent AHA/ACC High Blood Pressure (BP) Guideline strongly recommends initiating SPC therapy for patients with stage 2 hypertension. However, translating recommendations into clinical practice remains challenging. Concerns regarding agent selection, safety, tolerability, cost, and long-term management, coupled with clinical inertia and workflow constraints, may limit uptake. In this Perspective, we review the evidence supporting SPC use and focus on implementation considerations relevant to primary care, highlighting strategies and evidence gaps that must be addressed to integrate SPCs into routine hypertension management and achieve population-level BP control.
Identifiers
42414804What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.